Catheter ablation has been wildly used to treat atrial fibrillation (AF) and has achieved a better efficacy for paroxysmal AF (PAF) but not for persistent AF (PerAF). Furthermore, a few data on the efficacy and safety of catheter ablation for PerAF were reported. This study aimed to investigate long-term efficacy of radiofrequency catheter ablation (RFCA) for PerAF and explore predictors of late recurrence of atrial fibrillation (LRAF).
Introduction
Catheter ablation has been wildly used in the treatment of atrial fibrillation (AF) since Haissaguerre et al [1] found pulmonary veins (PVs) are an important trigger of AF and has achieved a better efficacy for PAF. [2, 3] Furthermore, with the development of novel technologies and strategies, as well as emerging evidence which catheter ablation as first-line therapy for PerAF is more effective than antiarrhythmic drugs (AADs), [4] current guidelines recommend catheter ablation is a Class IIa indication for symptomatic perAF. [5, 6] However, data on PerAF ablation relatively limited, and long-term success rate was low and marked variations with different ablation techniques and strategies. [7] [8] [9] Therefore, this study aimed to investigate the long-term efficacy of different radiofrequency catheter ablation (RFCA) strategies for PerAF and explore the predictors of late recurrence of atrial fibrillation (LRAF).
Methods

Study design
In this study, we defined LRAF as AF recurrence after AF ablation 3 months. According to this definition, the follow-up patients were divided into AF recurrence group and no-recurrence AF group, and a retrospective case-control study was conducted to analyze the data from our single electrophysiology center to clarify long-term efficacy of RFCA for PerAF and predictors of LRAF.
Study population
In this study, 92 consecutive patients (64 males) with PerAF were enrolled. PerAF is defined as continuous AF lasting more than 7 days or requiring cardioversion between 48 hours and 7 days. monitoring (including previous electrocardiogram [ECG] or Holter). All patients accepted transesophageal echocardiography evaluations to exclude LA thrombus. Pulmonary vein computed tomography (PVCT) was also performed before ablation to clear the PV anatomy, measure each PV diameter, and calculate the degree of roundness of each PV. The roundness of each PV was expressed by venous ostium index (VOI) of PV, which is equal to the anterior-posterior diameter (APD) of each PV divided by the superior-inferior diameter (SID). A larger VOI indicates a rounder PV. The exclusion criteria were as follows: previous ablation for AF at another institution or only focal ablation without CPVI at the first ablation; loss to follow-up after ablation; valvular heart disease; and uncontrolled heart failure. All patients provided written informed consent before the procedure, and the protocol was approved by Ethics Committee in Second Affiliated Hospital of Chongqing Medical University.
Catheter ablation procedure
Patients were asked to stop anti-arrhythmic drugs (AADs) for 5 half-lives before ablation and oral anticoagulation therapy was replaced by low molecular weight heparin (LMWH) for 3 days up to 12 hours before ablation. PV angiography was firstly performed to verify the PVs ostia and atrium. Subsequently, the LA three-dimensional electroanatomy was constructed guided by the CARTO mapping system (Biosense-Webster) and used Carto image integration module to obtained image integration of PVCT image with constructed electroanatomy to real-time navigate ablation catheter. Then, irrigated RFCA was performed guided by the CARTO mapping system and single Lasso ring electrode (Biosense-Webster). First, CPVI was performed at the PVs atrium with a 3.5-mm irrigated-tip ablation catheter (Navistar, Biosense-Webster). The endpoint of CPVI was to achieved complete electrical isolation of PV, that is, there is no conduction between PV and LA (entrance block and exit block). If AF did not terminate after CPVI, additional ablation (including linear, complex fractionated atrial electrograms (CFAE) ablation or both) would be performed. First, an additional roof line and/or a mitral isthmus line were performed. Subsequent, if this additional line ablation still did not terminate AF, other additional different atrial linear ablations were performed at LA anterior and posterior wall, septum, ridge between the LA appendage and LSPV, coronary sinus, the superior vena cava, or tricuspid isthmus based on the CARTO map. After that, if AF termination still failed, CFAE-targeted ablation was performed based on the CARTO map. The linear ablation endpoint was bidirectional conduction block across the linear lesions. CFAE was defined as described previously [10] and the endpoints are the elimination of detectable CFAE site. Finally, if AF was not terminated by the above ablation procedures, we administered intravenous pharmacologic cardioversion, direct current cardioversion or both methods.
Postablation care
After the procedure, all patients were hospitalized for 3 days to continuously monitor rhythm. All patients were routinely administered AADs for 3 months and were administered with LMWH via subcutaneous injection for 3 days followed by warfarin with a target international normalized ratio of 2 to 3 or dabigatran for 2 to 3 months, and thereafter whether anticoagulation was continued according to the CHADS2 score. If CHADS2 score ≥2, anticoagulation should be continued.
Follow-up
In this study, 3-month blanking period was applied. AF recurrence was defined as the occurrence of AF, atrial flutter (AFL), atrial tachycardia (AT) of at least lasting 30 seconds that was confirmed by an ECG or Holter monitoring. ERAF was defined as AF recurrence within 3-month blanking period; LRAF was defined as AF recurrence after the blanking period. After discharge, patients were followed-up routinely at 1, 3, 6, 9, 12, 18, and 24 months and once yearly thereafter, and BP measurement, 12-lead surface ECG, 24-hour Holter, and echocardiography were performed. In addition, patients may return to the outpatient clinic for followup when they had palpitations or other symptoms at any time. If AF recurrence was observed, AADs were first administered to restore and maintain SR and repeat ablation were recommended after the blanking period.
Repeat ablation
The PV-LA conduction was first evaluated in reabation procedure. If PV-LA conduction restored, CPVI was performed to close all PV-LA conduction gaps. If necessary, additional ablation strategies, similar with the first procedure, were performed. If no PV reconnection was observed, linear, CFAE or both ablations were performed except CPVI.
Statistical analysis
Statistical analysis was performed using SPSS 20.0 software. Continuous variables were presented as mean ± SD or median with interquartile range (IQR) (25th, 75th percentile), and categorical variables were expressed as percentages. The differences between groups were compared using an Independentsample Student's t-test. Chi-square statistics (or Fisher's exact test if applicable) were used for categorical variables to compare differences between groups. All the variables with P-value (P) < .1 in the univariate analysis were selected to the multiple variables logistic regression model. Multiple logistic regression analysis (forward selection method) was used to evaluate predictors of LRAF after a single procedure, calculating the odds ratio (OR), and 95% confidence intervals (CI). Survival analysis was completed using Kaplan-Meier survival curves and log-rank test. A 2-tailed value of P < .05 was regarded as statistically significant.
Results
Patient profile
Clinical baseline characteristics of 92 patients are presented in Table 1 . The mean age was 56.42 ± 11.24 years, mean AF duration 41.33 ± 39.52 months (median 24 months, IQR, 9-60 months), mean LAD was 41.38 ± 4.22 mm and mean LVEF (%) was 63.89 ± 9.19; right-side PVs were larger than left-side PVs (P < .001); superior PVs were larger than inferior PVs (P < .001); and VOI of right-side PVs was larger than that of left-side PVs (P < .001). According to the long-term follow-up results after a single procedure, 92 patients were divided into recurrence group (55 patients) and no recurrence group (37 patients). Ablation strategies were no difference between groups (P = .226); AF duration between the recurrence group and no recurrence group were 50.22 ± 42.40 mm vs 28.11 ± 30.85 mm (P = .005), and variations in the number of PVs also exhibited statistical differences between groups (P = .037) ( Table 2) . 
Clinical outcome
All 92 patients underwent RFCA were followed-up and no death occurred during follow-up period.
Clinical outcome after a single procedure
After a median follow-up 15 (IQR 12-34) months, 55 (59.8%) patients experienced AF recurrence. AF recurrence after a single procedure was 48.9%, 55.4%, 58.7%, and 59.8% at 1, 2, 3, and 4 years, respectively, and 92.7% of AF recurrences occurred in the first 2 years. Long-term free-AF survival after a single procedure was 40.2% ( Fig. 1 ).
In the first procedure, 33 (35.9%) patients underwent CPVI alone, 46 (50.0%) CPVI plus linear ablation, 1 (1.1%) CPVI combined CFAE ablation and 12 (13.0%) CPVI combined linear and CFAE ablation. Long-term SR maintenance was no different between CPVI alone and CPVI plus additional ablation (48.5% vs 35.6%, log-rank test, P = .165). In addition, 52 patients experienced ERAF and long-term SR maintenance was lower in patients with ERAF than those without (17.3%% vs 70%, log rank test, P < .001). Furthermore, arrhythmia types in 55 patients with LRAF included 42 cases of AF, 11 cases of AFL and 2 cases of AT, and 23 of LRAF patients (13 AF, 10 AFL) received the second procedure. In the second procedure, we found PV-LA reconduction restored in 15 patients (65%), and the prevalence of PV-LA reconnections were similar in patients with ERAF and initial AF recurrence after the blanking period (66.7% vs 50.0%, P = .636).
Clinical outcome after multiple procedures
After a mean of 1.3 ± 0.6 procedures with median follow-up 26 (IQR, 14-42) months, 44 (47.8%) patients suffered AF recurrence. AF recurrence after multiple procedures was 32.6%, 44.6%, 46.7%, 46.7%, 46.7%, and 47.8% at 1, 2, 3, 4, 5, and 6 years, respectively, and 93.2% of AF recurrence still occurred in the first 2 years. Long-term free-AF survival after multiple procedures was 52.2% (Fig. 2) . Around 28 repeat procedures were performed and the distribution of which was 2 in 19 patients, 3 in 3 patients, 4 in 1 patient. The maintenance rate of SR was 40.2%, 51.1%, 52.2%, 52.2% after the 1, 2, 3, and 4 procedures, respectively. The distribution of ablation strategies was as follows: 39 (32.5%) CPVI alone, 70 (58.3%) CPVI combined additional ablation, and 11 (9.2%) other ablation strategies without combined CPVI. Yubing
Predictors of the LRAF after a single procedure
In univariate analysis, the factors of AF recurrence (P < .1) included AF duration, BMI, RSPVSID, RSPVAPD, variations in the number of PVs, and ERAF after a single procedure. These factors were included in a multivariate logistic regression model and regression analysis results demonstrated that AF duration (OR = 1.015, 95%CI 1.001-1.030, P = .038) and ERAF (OR = 10.654, 95%CI 3.853-29.460, P < .001) were predictors of LRAF after a single procedure (Table 3) . Additionally, according to the median (24 months) of AF duration, patients were divided into those with AF duration of < 24 months (n = 36) and those with AF duration of ≥24 months (n = 56). The baseline characteristics are summarized in Table 4 . It can be seen from Table 4 , except for younger age in patients with AF duration of < 24 months (P = .001), other baseline data was no difference between 2 groups. Survival analysis indicated long-term SR maintenance rate was higher in patients with AF duration of <24 months than those with AF duration of ≥ 24 months (55.6% vs 30.4%, log rank test, P = .021) after a single procedure.
Complications
There was no procedure-related death and the complication rate for all 120 procedures was 5.8%. Details were as follows: 3 (2.5%) cardiac tamponade, 1 (0.8%) transient ischemic attack (TIA), 1 (0.8%) symptomatic PV stenosis, 1 (0.8%) hematoma, and 1 (0.8%) pseudoaneurysm. 
Discussions
Main findings
In this study, the main findings are the following: Long-term SR maintenance rate was 52.2% with 2-year follow-up after multiple RFCA procedures; almost all AF recurrence occurred in the first 2 years regardless of after single-and multiple-procedure; repeat ablation increased the maintenance rate of SR; More than half of all ablation strategies was CPVI plus additional ablation regardless of after single-and multiple-procedure but CPVI plus additional ablation did not decrease AF recurrence; and AF duration and ERAF were predictors of LRAF after a single procedure; furthermore, patients with AF duration of < 24 months had better outcome.
Ablation strategy and long-term efficacy of catheter ablation for PerAF
The mechanism of trigger and maintenance of PerAF is complex. Non-PV triggers of AF are common and play an important role in patients with PerAF. [11, 12] Therefore, additional ablation targeting non-PV triggers based on PVI is often required in patients with PerAF. However, whether additional ablations can improve outcome remains contentious and the success rate varies with studies. [7] [8] [9] [13] [14] [15] [16] Brooks et al [7] reported the success rate was higher with PVI plus additional ablation than with PVI alone (38%-62% vs 21%-22%); Elayi et al [13] reported additional ablation increased 16-months SR maintenance rate after a single procedure; Scherr et al [14] reported stepwise ablation strategy ending with AF termination improve 5-year AF ablation success rate. However, RASTA study indicated that in PerAF patients, additional substrate modification beyond PVI does not improve single procedure outcome. [15] Atienza et al [16] reported CPVI plus high-frequency source ablation offered no incremental value for PerAF. Furthermore, a recent large randomized controlled trial reported neither linear ablation nor CFAE ablation in addition to PVI decrease AF recurrence. [9] In this study, we also found additional ablation based on CPVI did not increased long-term SR maintenance rate compared with CPVI alone after a single procedure. Its reason is unclear. Additional ablation may cause new arrhythmogenic substrates formation and these substrates may result in AF recurrence, which may impair any benefits regarding additional ablation. However, a meta-analysis showed PVI with limited linear ablation within the left atrium significantly reduced AF recurrence while more extensive linear lesion or biatrial ablation not. [17] Therefore, accurately localizing non-PV foci and limited additional ablation using different ablation strategies such as combined cryoballoon and radiofrequency ablation method [18] is necessary. In this study, except 2 empirical lines, we also ablate in other non-PV triggers based on the CARTO mapping results because ablation of these triggers maybe benefits. [19] We did not perform subanalysis of each specific additional ablation line because sample is small. Now, we are continuing to expand our sample size to further analyze the impact of each specific ablation line on ablation outcomes to detect more accurate additional ablation line and develop optimal ablation strategies for PerAF.
Predictors of LRAF after a single procedure
Previous studies have identified some predictors for LRAF, including early recurrence, LA size, AF duration, and failure to terminate AF by ablation and so on, [8, 10, 14, [20] [21] [22] but the predictors of AF recurrence were inconsistent among different studies. In present study, we found AF duration and ERAF were predictors of LRAF after a single procedure while LAD not. In this study, LAD was not a predictor of LRAF probably because LAD was only 41 mm much smaller than that in other studies. [14, 22] Predictors of LRAF after a single procedure by logistic regression analysis. Data are expressed as mean ± SD or n (%). AF = atrial fibrillation, APD = anterior-posterior diameter, BMI = body mass index, CHD = coronary heart disease, LAD = left atrial diameter, LIPV = left inferior pulmonary vein, LSPV = left superior pulmonary vein, LVDd = left ventricular end-diastolic diameter, LVEF = left ventricular ejection fraction, PVCT = pulmonary vein computed tomography, RIPV = right inferior pulmonary vein, RMPV = right middle pulmonary vein, RSPV = right superior pulmonary vein, SID = superior-inferior diameter, VOI = venous ostium index. AF duration is a predictor of LRAF and has been confirmed by many studies. [8, 10, 14, 20, 21] Matsuo et al [20] reported AF duration was longer in patients with recurrence than those without (57 ± 54 months vs 23 ± 21 months, P < .0001), further identified AF recurrence after the final ablation was higher in patients with AF duration > 21 months. Scherr et al [14] identified AF duration ≥18 months predicted AF recurrence. Tilz et al [8] also reported AF duration independently predicted AF recurrence and patients with AF duration < 2 years had a significantly higher success rate than those of AF duration > 2 years. In this study, we found AF duration was a predictor of LRAF. Furthermore, Patients with AF duration 24 months had higher long-term SR maintenance rate. This may be attributed to an increase of arrhythmogenic substrates with longer AF duration. [11, 12, 23] Therefore, ablation for PerAF should be performed at early phase of AF.
Additionally, in this study, we found ERAF was also a predictor of LRAF after a single procedure. ERAF is common after ablation and some patients with ERAF did not again experience AF recurrence during the subsequent long-term follow-up. [24] Furthermore, ERAF is generally considered to be due to acute thermal injury and inflammatory response caused by radiofrequency energy and a transient reversible process. [25, 26] However, previous studies also found patients with ERAF have lower long-term SR maintenance rate than patients without ERAF and identified ERAF can predict LRAF. [21, 27] These results suggest ERAF, except for catheter-induced transient trauma, also has other mechanisms. Indeed, Lellouche et al [28] reported in143 PAF and PerAF patients with ERAF underwent a second ablation, 59% of cases had PV-LA reconnection. Yanagisawa et al [29] reported in 66 PAF and PerAF patients with ERAF underwent early reablation, 77% patients had PV reconnection. Furthermore, Miyazaki et al [30] reported the prevalence of PV reconnections and non-PV foci were similar between patients with ERAF and those with recurrence beyond the blanking period. In this study, we also found that the prevalence of PV-LA reconnections was no difference between patients with ERAF and initial AF recurrence after the blanking period in second procedure. These results implied PV-LA reconnections are responsible for ERAF. Therefore, ERAF is attributed to not only catheter-induced transient trauma but also PV-LA reconnection and non-PV foci. In addition, Lellouche et al [28] reported early reablation within the blanking period can improve LRAF but increased the number of procedures. Yanagisawa et al [29] reported early reablation increased the number of procedures and was not beneficial for PerAF. These suggest reablation of ERAF may be more appropriate after blanking period to avoid potential risks and some unnecessary reablation.
Limitation
Because ECG and 24-hour Holter was performed at intermittent regular follow-up time and the time of symptoms to detect AF recurrence, some asymptomatic AF may have remained undetected, which may lead to underestimate AF recurrence. Therefore, it is necessary to continuously monitor the patient's rhythm during the follow-up period to know the real world of AF recurrence. In addition, we only found that PV-LA reconnection and non-PV foci accounted for a large proportion in patients with AF recurrence in the second ablation procedure but cannot identity their respective triggering role in the AF recurrence. Also, this study is a retrospective study therefore its results need further confirmed by prospective studies.
Conclusion
Approximately 50% or more patients with PerAF can maintain SR with a median over 2-year follow-up by multiple ablation procedures. Additional ablation based on CPVI did not increased long-term SR maintenance rate. AF duration and ERAF were predictors of LRAF after a single procedure. Patients with AF duration < 24 months had superior outcome. Therefore, PerAF should be performed at early stage in the course of the AF journey.
